Evidence map›Paper›PMID 25891774›Full record

ArticleACS chemical neuroscience2015

Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias.

Kimberly M Lovell, Kevin J Frankowski, Edward L Stahl, Stephen R Slauson, Euna Yoo, Thomas E Prisinzano, Jeffrey Aubé, Laura M Bohn

Erratum issuedAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 58 citations in OpenAlex.

  1. Triazole 187 is a biased KOR agonist that suppresses itch without sedation and induces anxiolytic-like behaviors in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Recommended Opioid Receptor Tool Compounds: ComparativeACS pharmacology & translational science · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Dopamine DThe international journal of biochemistry & cell biology · 2022
    Article
  12. Review
  13. Review
  14. Functional Selectivity of Dopamine DInternational journal of molecular sciences · 2021
    Review
  15. BiasNet: A Model to Predict Ligand Bias Toward GPCR Signaling.Journal of chemical information and modeling · 2021
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Strategies for DevelopingThe Journal of pharmacology and experimental therapeutics · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kimberly M Lovell†Departments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.
Kevin J Frankowski‡Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
Edward L Stahl†Departments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.
Stephen R Slauson‡Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
Euna Yoo‡Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
Thomas E Prisinzano‡Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
Jeffrey Aubé‡Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
Laura M Bohn†Departments of Molecular Therapeutics and Neuroscience, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, United States.
University of Kansas · USScripps Research Institute · US

Funding

Novel Probes of the Kappa Opioid Receptor: Chemistry, Pharmacology, and BiologyR01DA031927 · NIDA · UNIVERSITY OF SOUTH FLORIDA · PI Jeffrey Aube, Laura M. Bohn · 2011 to 2026
$8.4M
NIDA NIH HHS R01 DA031927
6 · The paper itself

Abstract

Kappa opioid receptor (KOR) modulation is a promising target for drug discovery efforts due to KOR involvement in pain, depression, and addiction behaviors. We recently reported a new class of triazole KOR agonists that displays significant bias toward G protein signaling over βarrestin2 recruitment; interestingly, these compounds also induce less activation of ERK1/2 map kinases than the balanced agonist, U69,593. We have identified structure-activity relationships around the triazole scaffold that allows for decreasing the bias for G protein signaling over ERK1/2 activation while maintaining the bias for G protein signaling over βarrestin2 recruitment. The development of novel compounds, with different downstream signaling outcomes, independent of G protein/βarrestin2 bias, provides a more diverse pharmacological toolset for use in defining complex KOR signaling and elucidating the significance of KOR-mediated signaling.

Indexed as

Analgesics, OpioidAnimalsArrestinsBenzeneacetamidesbeta-ArrestinsCHO CellsCricetulusDose-Response Relationship, DrugDrug DiscoveryGTP-Binding ProteinsHumansMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PhosphorylationPyrrolidinesReceptors, Opioid, kappaAnalgesics, OpioidArrestinsBenzeneacetamidesbeta-ArrestinsGTP-Binding ProteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PyrrolidinesReceptors, Opioid, kappaRecombinant ProteinsU 69593arrestinbiased agonismFunctional selectivityGPCRG protein couplingMAP kinase

Identifiers

PMID25891774
PMCPMC4830356
OpenAlexW2323301233

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.